Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
To overcome these limitations, ABT-263 (Navitoclax), a derivative of ABT-737, was developed as an orally bioavailable pan-BCL inhibitor (62)
while the EU, Australia, and New Zealand allowance of up to 25% erucic acid comes with a TDI of 7 mg/kg body weight [99]
The cytosolic GSTs (cGSTs) have been subgrouped into numerous divergent classes on the basis of their chemical, physical and structural properties [39], [70]
J Biol Chem 277 (51): 49446
Always prioritize sterile technique and proper storage to maintain compound integrity
.webp)
US$ 20.87
US$ 20.33
US$ 20.11
US$ 23.20
